Alectinib versus crizotinib in ALK-positive advanced non-small cell lung cancer and comparison of next-generation TKIs after crizotinib failure: Real-world evidence.

Cancer Med · 2022 · PMC9741982 · PMID 35616090

Europe PMC DOI

hedged sentence

0.0710

closest p · 1.4× alpha

0.0710

boldest claim

The sentences

approached significancep = 0.071so close (0.05 < p ≤ 0.1)

20 In our analysis, the survival of patients with v1 variant was better than others, and the statistical difference approached significance (HR: 0.56, p = 0.071).

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.